Allow patents for incremental innovation of medicines: StudyAugust 26th, 2009 - 9:22 pm ICT by IANS
New Delhi, Aug 26 (IANS) India should give patents to improved variants of existing medicines as it will help people access variety of drugs at a competitive price, said a new study released Wednesday.
“Currently Indian patent law does now give patent to a new drug if it is not significantly different and efficacious than an existing one,” said Ranjit Shahani, president of the Organisation of the Pharmaceutical producers of India (OPPI).
He said the government does not allow patent to incremental innovation which is a build-up innovation on an existing variety of medicine. This restriction is hurting Indian patients as they are not getting better medicines.
The report which was released by the US-India Business Council (USIBC) said that over 60 percent of the drugs on World Health Organisation (WHO) list of essential medicines reflect incremental improvements of older drugs.
“Extending patent protection to incremental pharmaceutical innovation should encourage Indian pharmaceutical companies to expand their investment in innovation and ultimately become major source of new drug products for both the Indian and global markets,” the report said.
Greg Kalbaugh, director of USIBC, said: “Incremental innovations are not small achievements.”
Giving an example, he said: “Heat stable version of anti-retro viral drugs may not be critically important to people in large cities where there is easy access to electricity and refrigeration, but they are surely important to people in rural areas.”
“Citizens in rural areas deserve to know that when they take an important drug, it is going to work whether they have access to refrigeration or not. Unfortunately, section 3 (d) of Indian patent law actively discourages that sort of innovations,” Kalbaugh argued.
He also said that 65 percent of the drugs approved by the US Food and Drug Administration between 1989 and 2000 are incremental innovations.
Shahani, who is also the managing director of Novartis India, said: “By talking about patent for incremental innovation, they are not shifting their focus from generic drugs.”
- New study on protecting new drugs in India - Jun 16, 2009
- Patents law provisions conflicting, Novartis tells SC - Sep 18, 2012
- Why don't you reduce cancer drug price, SC asks Novartis - Sep 11, 2012
- SC again asks Novartis to cut cancer drug price - Sep 12, 2012
- India urges international community to promote generic drugs - Jun 09, 2011
- Remove non-tariff barriers in pharma sector: India - Jul 03, 2012
- Don't block affordable Indian medicines, EU urged - Dec 10, 2010
- Huge potential seen in US-India business ties - Apr 29, 2012
- US-India business summit sees huge potential (Lead, changing dateline) - Apr 29, 2012
- US trade group sends life sciences mission to India - Jan 31, 2012
- Fridge most important innovation in food history - Sep 14, 2012
- New drug shows promise in treating Fragile X - Jan 08, 2011
- Victory for access to medicines as Valaganciclovir patent is overturned - May 07, 2010
- Trips plus measures outside WTO framework not acceptable: Anand Sharma - Apr 26, 2011
- US puts India, China, Pakistan on IPR watch list - May 02, 2012
Tags: business council, food and drug administration, global markets, incremental improvements, incremental innovation, incremental innovations, india business, indian patients, indian pharmaceutical companies, oppi, patent law, patent protection, pharmaceutical innovation, pharmaceutical producers, refrigeration, stable version, us food and drug administration, usibc, viral drugs, world health organisation